The clinical utility of tuberculin skin test and interferon-γ release assay in the diagnosis of active tuberculosis among young adults: a prospective observational study

Ji Eun Lee, Hee-Jin Kim, Sei Won Lee, Ji Eun Lee, Hee-Jin Kim, Sei Won Lee

Abstract

Background: The roles of the tuberculin skin test (TST) and QuantiFERON®-TB Gold In-Tube assay (QFT-IT) in the diagnosis of active tuberculosis (TB) are not clear in young adults. We evaluated the diagnostic accuracy of the TST and QFT-IT in smear-negative TB among young adults with no underlying disease.

Methods: We prospectively enrolled 166 young participants 20-29 years of age with suspected active TB in a military hospital of South Korea. The TST and QFT-IT were performed for all participants.

Results: Of the 143 patients included in the analysis, active TB was diagnosed in 100 (69.9%). There were 141 male patients, none of whom had immunosuppressive disease. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of TST were 94% (95% CI, 87-98%), 88% (95% CI, 74-96%), 95% (95% CI, 88-98%), and 86% (95% CI, 72-94%), respectively. The sensitivity, specificity, PPV, and NPV of the QFT-IT were 93% (95% CI, 86-97%), 95% (95% CI, 81-99%), 98% (95% CI, 92-99%), and 84% (95% CI, 69-93%), respectively. No significant differences were found between the TST and QFT-IT in any statistic.

Conclusions: Both the TST and QFT-IT showed high sensitivity and specificity in differentiating active TB from other diseases. The diagnostic accuracy of these two tests did not differ significantly when applied to this clinical population of young, immunocompetent adults in whom neonatal BCG vaccination was common, there was no history of previous TB and in whom suspicion of TB was high.

Trial registration: ClinicalTrials.gov: NCT00982969.

References

    1. World Health Organization(WHO) report 2009. Global tuberculosis control. Accessed 1 Feb 2010.
    1. World Health Organization(WHO) Global TB database. Accessed 1 Feb 2010.
    1. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376–1395.
    1. Laszlo A, Gill P, Handzel V, Hodgkin MM, Helbecque DM. Conventional and radiometric drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol. 1983;18(6):1335–1339.
    1. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet. 2003;362(9387):887–899. doi: 10.1016/S0140-6736(03)14333-4.
    1. Rapid diagnostic tests for tuberculosis: what is the appropriate use? American Thoracic Society Workshop. Am J Respir Crit Care Med. 1997;155(5):1804–1814.
    1. Kang YA, Lee HW, Hwang SS, Um SW, Han SK, Shim YS, Yim JJ. Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis. Chest. 2007;132(3):959–965. doi: 10.1378/chest.06-2805.
    1. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest. 2008;133(5):1196–1202. doi: 10.1378/chest.07-1995.
    1. Park SY, Jeon K, Um SW, Kwon OJ, Kang ES, Koh WJ. Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scand J Infect Dis. 2009;41(11-12):818–822. doi: 10.3109/00365540903214298.
    1. Sester M, Sotgiu G, Lange C, Giehl C, Girardi E, Migliori GB, Bossink A, Dheda K, Diel R, Dominguez J, Interferon-{gamma} release assays for the diagnosis of active tuberculosis: A systematic review and meta-analysis. Eur Respir J.
    1. Bianchi L, Galli L, Moriondo M, Veneruso G, Becciolini L, Azzari C, Chiappini E, de Martino M. Interferon-gamma release assay improves the diagnosis of tuberculosis in children. Pediatr Infect Dis J. 2009;28(6):510–514. doi: 10.1097/INF.0b013e31819abf6b.
    1. Baba K, Sornes S, Hoosen AA, Lekabe JM, Mpe MJ, Langeland N, Dyrhol-Riise AM. Evaluation of immune responses in HIV infected patients with pleural tuberculosis by the QuantiFERON TB-Gold interferon-gamma assay. BMC Infect Dis. 2008;8:35. doi: 10.1186/1471-2334-8-35.
    1. Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest. 2009;135(4):1010–1018. doi: 10.1378/chest.08-2048.
    1. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177–184.
    1. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis. 2006;10(11):1192–1204.
    1. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54(RR-15):49–55.
    1. Im JG, Itoh H, Lee KS, Han MC. CT-pathology correlation of pulmonary tuberculosis. Crit Rev Diagn Imaging. 1995;36(3):227–285.
    1. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, Noma S. Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. Radiology. 1993;186(3):653–660.
    1. Im JG, Webb WR, Han MC, Park JH. Apical opacity associated with pulmonary tuberculosis: high-resolution CT findings. Radiology. 1991;178(3):727–731.
    1. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174. doi: 10.2307/2529310.
    1. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005;293(22):2756–2761. doi: 10.1001/jama.293.22.2756.
    1. Ildirim I, Hacimustafaoglu M, Ediz B. Correlation of tuberculin induration with the number of Bacillus Calmette-Guerin vaccines. Pediatr Infect Dis J. 1995;14(12):1060–1063. doi: 10.1097/00006454-199512000-00006.
    1. Sepulveda RL, Heiba IM, King A, Gonzalez B, Elston RC, Sorensen RU. Evaluation of tuberculin reactivity in BCG-immunized siblings. Am J Respir Crit Care Med. 1994;149(3 Pt 1):620–624.
    1. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, Hijjar MA, Dourado I, Cruz AA, Sant'Anna C. et al.Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005;366(9493):1290–1295. doi: 10.1016/S0140-6736(05)67145-0.
    1. Raby E, Moyo M, Devendra A, Banda J, De Haas P, Ayles H, Godfrey-Faussett P. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PLoS One. 2008;3(6):e2489. doi: 10.1371/journal.pone.0002489.
    1. Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, Tsai HC, Wann SR, Lin HH, Liu YC. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection. 2009;37(2):96–102. doi: 10.1007/s15010-008-8082-3.
    1. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M. et al.Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med. 2004;170(1):59–64. doi: 10.1164/rccm.200402-179OC.
    1. Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J. 2007;30(5):945–950. doi: 10.1183/09031936.00040007.
    1. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med. 2000;161(4 Pt 2):S221–247.
    1. Wang L, Turner MO, Elwood RK, Schulzer M, FitzGerald JM. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax. 2002;57(9):804–809. doi: 10.1136/thorax.57.9.804.

Source: PubMed

3
Abonner